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Abstract
We have recently isolated novel IFN-inducible gene, Gene associated with Retinoid-Interferon-induced Mortality-1 (GRIM-1),
using a genetic technique. Moderate ectopic expression of GRIM-1 caused growth inhibition and sensitized cells to retinoic
acid (RA)/IFN-induced cell death while high expression caused apoptosis. GRIM-1 depletion, using RNAi, conferred a growth
advantage. Three protein isoforms (1a,1 b and 1c) with identical C-termini are produced from GRIM-1 mRNA. We show that
GRIM-1 isoforms interact with NAF1 and DKC1, two essential proteins required for box H/ACA sno/sca RNP biogenesis and
suppresses box H/ACA RNA levels in mammalian cells by delocalizing NAF1. Suppression of these small RNAs manifests as
inefficient rRNA maturation and growth suppression. Interestingly, yeast Shq1p also caused growth suppression in
mammalian cells. Consistent with its growth-suppressive property, GRIM-1 expression is lost in a number of human primary
prostate tumors. Our observations support a recent study that GRIM-1 might act as a co-tumor suppressor in the prostate.
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Introduction
The IFN family of cytokines suppress abnormal cell growth by
two mechanisms: 1) directly activating growth arrest/apoptosis in
the neoplastic cells [1] and 2) shaping the immune response
against neoplastic cells [2]. Among the known direct effects of
IFNs on mRNA are - 1) degradation by 29,59A-dependent RNaseL
[3]; 2) inhibition of cap-dependent translation initiation by PKR
via phosphorylation of eIF-2a; 3) sequestration of eIF3 by p56 [4]
and 4) mTOR-dependent phosphorylation of cap-binding factor
eIF4E-BP1 [5]. We and others have shown that combination of
IFNs with cell-differentiating agents such as retinoic acid (RA)
effectively suppresses tumor growth in clinical and experimental
models [1]. To understand the molecular mechanisms that
regulate these processes, we employed a genome-wide knockdown
method and isolated GRIMs [6,7]. One such novel gene product
GRIM-1, suppressed cell growth [8]; and exhibited similarity
(,53%) to a yeast protein, Shq1p. Here, we describe a mechanism
by GRIM-1 that controls mature rRNA levels and cell growth.
The synthesis and maturation of rRNA and its assembly with
ribosomal proteins plays a central role in regulating cell growth.
A hallmark observed in all cancers relate to gain of ribosome
function resulting in high synthetic capacities [9,10], while defect(s)
still contribute to pathological conditions as seen in Diamond
Blackfan anemia [11] and Dyskeratosis Congenita (DC) [12] that
often result in bone marrow failure without affecting other tissues.
In addition, diverse several cellular signals/stress pathways appear
to control the activity of ribosome assembly and function [13–15].
Thus, a comprehensive analysis of these pathways will improve
our current understanding of gain, loss and/or mutations as has
been recently shown for breast [16] and prostate [17] cancers to
design effective therapeutic strategy.
Maturation of rRNA requires at least hundred or more trans-
acting protein factors, in addition to the ribosomal proteins, and
numerous nucleotide modifications. A group of small non-coding
RNAs, the H/ACA RNAs, serves as pseudouridylation guides in
assisting dyskerin (DKC1; also known as Nap57 in rodents and
Cbf5p in yeast) to catalyze such modification. GRIM-1 (also
known as SHQ1 in mammals and Shq1p in yeast) and NAF1
(Naf1p in yeast) are factors that determine and/or regulate the
stability of DKC1. In budding yeast, Shq1p depletion resulted in
poor growth due to a problem in rRNA maturation [18]. It forms
complexes with other proteins viz., Naf1p [19] and a pseudouri-
dine synthetase (Cbf5p) [20] that are required for the biogenesis of
small nucleolar (sno) ribonucleoprotein particles (RNPs) (snoRNPs),
small Cajal body (sca) RNPs and telomerase RNA component (terc)
RNPs required for rRNA maturation, spliceosomal RNA (snRNA)
modifications and telomerase activity, respectively. A role for NAF1
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have been described [21–23]. We show here that human GRIM-1
suppresses cell growth by sequestering NAF1, leading to a loss of
box H/ACA RNAs and mature rRNA levels. We also show that
yeast Shq1p acts as a growth suppressor in GRIM-1-depleted
human cells. These studies uncovered a novel regulatory pathway
that controls cell growth by limiting rRNA maturation. The
biological relevance of our observations is further attested by a loss
of GRIM-1 expression in primary human prostate tumors. In this
manuscript we use a) GRIM-1 in our experiments, b) SHQ1/SHQ1
when referring to published articles on the mammalian gene/
protein andc)shq1/Shq1p when referringtothe yeastgene/protein.
Materials and Methods
Plasmids and Cell lines
Human GRIM-1 isoforms (a, b and c) in pCXN2-Myc and
pEGFP-C2 vectors which express GRIM-1 as Myc and GFP-
tagged proteins at C and N termini, respectively have been
described [8]. The yeast shq1 ORF (Open Biosystems) was sub-
cloned into pCXN2-FLAG vector, to express as an N-terminally
FLAG-tagged protein. pLVX-Puro vector (Clontech) was used to
produce viral particles expressing GRIM-1 as per our previous
studies [24]. Stable cell lines with the indicated gene, either in
MCF-7 and/or HeLa (available from ATCC) were generated after
selecting with appropriate drug for 1 week to obtain colonies.
Colonies (n=50–75) were pooled and propagated further to avoid
a clonal bias in experiments. Cell growth was measured using a
colorimetric assay described earlier [25]. All work involving
recombinant DNA and/or viral vectors were approved by the
Institutional Biosafety Committee of the University of Maryland
Baltimore (No. IBC-00000875).
RNAi
A commercially available lentiviral vector (pLKO1) carrying a
shRNA capable of targeting human GRIM-1 (Open Biosystems)
was used for depleting endogenous GRIM-1 levels. An empty
vector and/or scrambled-shRNA control were used for demon-
strating the specificity of knockdown. Stable cell lines were
generated after transducing with lentivirus. A non-targetable
(RNAi-resistant) variant of GRIM-1 was generated using PCR
(Table S1) and expressed from pCXN2-Myc vector.
Antibodies and other reagents
Antibodies specific for Myc-tag (Cell Signaling), FLAG-tag and
actin (Sigma-Aldrich), GRIM-1 (developed in our lab), DKC1
(Santa Cruz Biotechnology), NAF1 (from Dr. Yves Henry, CNRS,
France), HRP-conjugated anti-mouse/rabbit IgG (GE Health-
care), Alexa FlourH 488-conjugated anti-mouse IgG (Invitrogen),
Cy3-conjugated anti-rabbit IgG (Jackson ImmunoResearch Lab-
oratories Inc) were used in Western blot (WB), Immunoprecipi-
tation (IP) and Immunofluorescence analyses in conjunction with
recombinant human IFN-b (Biogen, Inc), RA, protease-inhibitor
cocktail, DAPI (Sigma-Aldrich) and ECL reagents (Pierce) as in
our earlier studies [8,24].
Quantitative reverse transcription PCR (qPCR)
Total RNA was employed for cDNA synthesis with gene-
specific primer mix (Table S1) using a commercially available kit
(Promega). The resultant cDNA was used as template for real-time
PCR with SYBR green dye (Sigma-Aldrich, Inc) and gene-specific
primers (Table S1). Relative levels of different small RNAs were
normalized to those of snRNA-U6. For rRNA processing, the Ct
value obtained using primers 6/1 and F/A represent the total 18S
and 28S rRNA (mature and unprocessed), respectively, present in
the preparation. The Ct values obtained using two different
primer sets (4/5 and 2/3) for 59ETS-18S and (D/E and B/C) for
ITS2-28S represent unprocessed rRNA present in the prepara-
tion. Fraction of unprocessed rRNA was calculated using the
averages of primer pairs 4/5 (unprocessed) over 6/1 (total) and
primer pairs 2/3 (unprocessed) over 6/1 (total) for 18S rRNA
while primer pairs D/E (unprocessed) over F/A (total) and primer
pairs B/C (unprocessed) over F/A (total) for 28S rRNA. For
additional information on primers refer Table S1. At least
triplicate reactions per primer pair for each sample were employed
in each experiment. Each experiment was repeated with three
separate batches of RNA and subjected to Student’s t-test to
determine statistical significance of the differences.
Ribonucleoprotein (RNP)-Immunoprecipitation (IP) (RNP-
IP) assay
Cells (2610
6) were incubated in medium with 2% paraformal-
dehyde for 15 min and washed thrice with PBS before lysis using
buffer (20 mM HEPES pH 7.0 containing 150 mM NaCl, 1%
Triton X-100, 0.1% SDS and 0.1% sodium deoxycholate, 2 mM
MgCl2). Lysates were centrifuged to remove debris and superna-
tants were incubated with rabbit anti-Dyskerin IgG (Santa Cruz))
or with an isotypic IgG control at 4uC overnight. Protein A/G-
sepharose was added to pull down anti-Dyskerin or control IgG.
The pellet was washed twice with the above buffer; bound RNA
was extracted, analyzed by real-time PCR for abundance. RNA
directly extracted from the same number of cells was used as a
control in this experiment to assess their yield in RNP-IP.
Results
GRIM-1 suppresses cell growth
To ascertain our earlier observation that anti-sense GRIM-1
conferred a growth advantage in the presence of RA/IFN [8], we
employed RNAi. For this experiment, we depleted GRIM-1 using
lentiviral vectors coding for a GRIM-1-specific shRNA, and monitored
growth in the presence of RA/IFN. Cells expressing an empty
vector and/or scrambled shRNA were used as controls. RA/IFN
robustly suppressed the growth of cells expressing either empty
vectororscrambledshRNA(Figure1A).Incontrast,cellsexpressing
GRIM-1-specificshRNAcontinued togrowinpresenceofRA/IFN.
Depletion of GRIM-1 was confirmed by performing a WB analysis
with a mouse monoclonal antibody that detects full-length GRIM-1
(Figure 1B). GRIM-1 levels were ,12% in presence of specific
shRNA compared to the empty vector and/or scrambled shRNA
controls.
The GRIM-1 mRNA codes for 3 isoforms viz., GRIM-1a,
GRIM-1b and GRIM-1c with identical C-termini [8]. In a com-
plementary experiment, HeLa cells transfected with GFP-tagged
GRIM-1 isoformswerechallenged withRA/IFN and apoptosiswas
(shrinkage/chromatin condensation/fragmentation), monitored as
earlier [8]. Apoptosis was highest in GRIM-1c-expressing cells
followed by GRIM-1b and GRIM-1a. However, in the presence of
RA/IFN, 3.5-fold increase in dying cells was evident in GRIM1b-
expressing cells followed by 2-fold increase in GRIM-1a-expressing
cells and only modest increase in GRIM-1c-expressing cells (Figure
1C). Thus, GRIM-1 appears to be a novel growth suppressor and/
or apoptosis inducer.
GRIM-1 interacts with NAF1
Since yeast Shq1p has been suggested to form a complex with
Naf1p and assist in the biogenesis of box H/ACA RNA/RNP
[18], we wanted to know if such interaction occurs in mammalian
GRIM-1 Suppresses Sno/ScaRNA
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GRIM-1 isoforms in HeLa cells and determined its interaction
with endogenous NAF1. First, expression of the individual GRIM-
1 isoforms was ascertained by performing a WB analysis with
Myc-tag-specific antibody (Figure 2A). NAF1 levels were compa-
rable (Figure 2A) under these conditions. However, expression of
GRIM-1c was lower compared to GRIM-1a/b when normalized
to actin signals (Figure 2A). Hence, we performed IP using signal-
normalized cell lysates using Myc-tag-specific antibody followed
by WB analysis with NAF1-specific antibody. All three GRIM-1
isoforms pulled down NAF1 efficiently as revealed by WB analysis
of the IP products (Figure 2B). The higher NAF1 signals observed
in GRIM-1c-expressing cells compared to GRIM-1a/b-express-
ing cells, is not due to higher expression of NAF1 in these lysates,
rather it is due to a higher lysate input. This blot was stripped and
reprobed with a Myc-tag-specific antibody to exclude differences
in the levels of immunoprecipitated GRIM-1 isoforms (Figure 2B).
These interactions were further confirmed by a reciprocal IP,
where a NAF1-specific antibody was used to pull down Myc-
tagged GRIM-1 isoforms (Figure 2C). These experiments for the
first time show that GRIM-1 isoforms associate with NAF1.
GRIM-1 delocalizes NAF1 from Nucleus
We next determined if GRIM-1 isoforms and NAF1 proteins
co-localize in situ. To address this, we expressed Myc-tagged
GRIM-1 isoforms in HeLa cells and tracked NAF1 using confocal
microscopy. In control cells, NAF1 was exclusively nuclear with
certain focal regions of intense staining (Figure 2D). In contrast,
most NAF1 was found outside the nucleus and a majority of it
superimposed with GRIM-1 isoforms (Figure 2D). To determine
the effects on endogenous proteins, we treated GRIM-1-depleted
HeLa cells with RA/IFN and tracked NAF1. Very little NAF1 was
present in nuclei of RA/IFN-treated control cells (SC), while
GRIM-1-depleted cells (GS) had higher levels of nuclear NAF1
(Figure 2E). This is consistent with an increase in GRIM-1 levels
upon RA/IFN treatment that accumulates more in the cytoplasm
(Figure 2F). Thus, GRIM-1 delocalizes NAF1. No such effect on
the nuclear localization of p300 was noted (data not shown).
To determine if RA/IFN, which induced GRIM-1, affected
NAF1 levels, RA/IFN-treated HeLa cell lysates were subjected to
WB with NAF1-specific antibody. No discernible change in NAF1
level occurred (Figure 2G). A comparable protein loading was
ascertained by re-probing these blots with an actin-specific
antibody (Figure 2G). On a similar line, overexpression of
GRIM-1 isoforms did not alter NAF1 levels (see Figure 2A).
GRIM-1 downregulates H/ACA RNAs
Since NAF1 was required for box H/ACA RNP biogenesis in
mammalian cells [21,22], the impact of GRIM-1-mediated NAF1
delocalization would be detrimental to cells. To address this, the
levelsof all three classes of small non-codingRNAthat haveboxH/
ACA motif in addition box C/D snoRNA and spliceosomal RNAs
were analyzed by qPCR in cells expressing GRIM-1 isoforms.
Indeed, the levels of box H/ACA (sno, sca and terc) RNAs were
significantly suppressed (p,0.05) in presence of GRIM-1 compared
to controls (Figure 3A). Interestingly, someof the spliceosomal RNA
(snRNA-U2) and box C/D snoRNA-U3 levels were also signifi-
cantly (p,0.05) suppressed in these cells (Figure 3A). GRIM-1c,
GRIM-1b and GRIM-1a had high, intermediary and lowest
inhibitory effect, respectively, on these small RNAs. The levels of
box C/D snoRNA-U13 were comparable in cells expressing
different GRIM-1 isoforms (Figure 3A). We next examined the
effectofGRIM-1 depletiononthesesmallRNAs.Weemployedtwo
cell lines expressing either an empty vector or a scrambled shRNA
as controls. Significantly (p,0.01), higher levelsof these small RNAs
were present in GRIM-1-depleted cells compared to controls
Figure 1. GRIM-1 is a novel growth suppressor. A) GRIM-1 depletion confers a growth advantage during RA/IFN stimulation. Top: Growth of
HeLa cells stably expressing pLKO1 (EV; #) or scrambled shRNA (SC; &) or GRIM-1-specific (GS; m) shRNA were monitored for 4 days in the presence
of a sub-lethal but growth-inhibitory concentration of hIFN-b (1000 U/ml) and RA (1 mM). GRIM-1-depleted cells continue to grow while the others
are inhibited by RA/IFN. B) Depletion of GRIM-1 ascertained by WB analysis using GRIM-1-specific antibody and actin-specific antibody was used as
loading control. GRIM-1 in GS cells represent ,12% compared to levels in EV and/or SC when normalized to corresponding actin levels. C) GRIM-1
over-expression sensitizes cells to RA/IFN-induced cell death. HeLa cells transiently expressing GFP-tagged GRIM-1 isoforms (Open bars) were
challenged with hIFN-b (2000 U/ml) and RA (2.5 mM) (Solid bars) for 12 h. Change in cell/nuclear appearance of GFP-positive cells was used as a
measure of cells undergoing apoptosis. Numbers to the side in WB indicate positions of protein markers.
doi:10.1371/journal.pone.0024082.g001
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PLoS ONE | www.plosone.org 3 September 2011 | Volume 6 | Issue 9 | e24082Figure 2. GRIM-1 isoforms interact with endogenous NAF1 in mammalian cells. HeLa cells transiently expressing Myc-tagged GRIM-1
isoforms were analyzed for interaction with NAF1 using the indicated antibodies. A) Expression levels of GRIM-1 isoforms (top), NAF1 (middle) and
actin (bottom) in the indicated transfectants. GRIM-1c levels are low compared to GRIM-1a/b when normalized to actin levels. No significant change
in NAF1 levels are observed upon GRIM-1 expression. B & C) Total cell lysates (signal-normalized lysate amount) were subjected to IP with the
indicated antibodies and subsequently analyzed by WB with the indicated antibodies. All GRIM-1 isoforms interact with NAF1. More NAF1 in GRIM-1c-
expressing cells is due to more lysate used for IP. D–E) GRIM-1 and NAF1 co-localize in situ. D) Confocal images of Myc-tagged GRIM-1 isoforms (green
channel) and NAF1 (red channel). Nuclei (blue channel) were visualized using DAPI. GRIM-1 isoforms and NAF1 complexes (yellow) can be seen in the
merged channel indicative of interaction in situ. Lobed nuclei appear with a high frequency in GRIM-1c-expressing cells. E) GRIM-1 is necessary for
delocalizing NAF1. Immunofluorescent images of GRIM-1 and NAF1 in the indicated cell lines at steady state and RA/IFN-stimulated state. In both cell
lines, NAF1 is nuclear at steady state. Upon RA/IFN stimulation, NAF1 is delocalized in SC cells, but not in GS cells. F) Confocal images of endogenous
GRIM-1. RA/IFN stimulation increases GRIM-1 that accumulates more in the cytoplasm. G) NAF1 levels are not influenced by IFN/RA treatment. Total
cell lysates were prepared at the indicated time point after RA/IFN treatment and analyzed using the indicated antibodies in WB. Numbers to the side
in WB indicate positions of protein markers.
doi:10.1371/journal.pone.0024082.g002
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(Figure 3B) under these conditions.
Restoration of GRIM-1 expression in GRIM-1-depleted
cells downregulates H/ACA RNAs
Since RNAi may some time cause off-target effects [26,27] and
RNAi-mediated GRIM-1 depletion does not distinguish the effects
of individual GRIM-1 isoforms, we next performed reconstitution
experiments. Since, the GRIM-1-specific shRNA targets a region
within the ORF, it will also target the transgene-derived mRNA
for degradation/inhibition. Hence, we designed a variant that
codes for wild-type amino acids in the shRNA-targeted region
(Figure 4A) that was resistant to degradation/inhibition by the
resident GRIM-1 shRNA. After ensuring the expression of variant
GRIM-1, in GRIM-1-depleted cells (Figure 4A), we quantified the
levels of small RNAs. Small RNA levels were significantly (p,0.05)
suppressed by the individual variant GRIM-1 isoforms compared
to the parent cell line (Figure 4B); in a manner similar to over-
expressed GRIM-1 isoforms (see Figure 3). The levels of box C/D
snoRNA-U13 did not differ in cells expressing variant GRIM-1
isoforms under these conditions (Figure 4B).
GRIM-1 represses rRNA processing
SnoRNA-directed modification and cleavage of the primary
rRNA transcript yields mature 18S, 5.8S and 28S rRNA and is
critical for the formation of mature ribosomes. Therefore, we next
quantified the effect of GRIM-1 isoforms on rRNA processing,
using primers that can distinguish the precursor and mature
human rRNA molecules. One of the primer annealing site
overlaps the processed region (junction-specific) and another
further downstream in the invariant region representing unpro-
cessed and total rRNA, respectively (Figure 5A). Since, an ordered
processing in the 59ETS region is vital for subsequent cleavages to
generate mature 18S rRNA, we analyzed 59ETS-18S rRNA
junction in cell lines expressing GRIM-1 isoforms. The invariant
portion of 18S served as the internal control in this analysis. A
similar strategy was used for analyzing 28S rRNA processing. Raw
data from the junction-specific primer was normalized using
invariant primer region and represented as fraction rRNA
unprocessed. As shown in Figure 5B, in presence of GRIM-1
isoforms the level of unprocessed rRNA was higher compared to
the control cell line. Under these conditions, GRIM-1c was the
most potent inhibitor of 59ETS-18S rRNA processing followed by
GRIM-1b and GRIM-1a. In GRIM-1-depleted cells, 59ETS-18S
junction was more efficiently processed than in the controls
(Figure 5C). Upon reconstitution of variant GRIM-1 isoforms into
GRIM-1-depleted cells, the inhibitory effect on 59ETS-18S rRNA
processing reappeared (Figure 5D). As noted with 59ETS-18S
region, GRIM-1 depletion increased processed ITS2-28S rRNA
compared to the controls (Figure 5E). Upon reconstitution of
variant GRIM-1 isoforms, the inhibitory effect on ITS2-28S
rRNA reappeared showing isoform-specific differences to a certain
extent (Figure 5F). In this assay, GRIM-1b and GRIM-1c
inhibited ITS2-28S processing equivalently (Figure 5F).
Figure 3. GRIM-1 regulates small non-coding RNA levels. Relative abundance was calculated with respect to spliceosomal RNA (snRNA-U6)
levels by real-time PCR. A) Levels of the indicated RNA in HeLa cells stably expressing Myc-tagged GRIM-1 isoforms. GRIM-1 isoforms differentially
suppress box H/ACA-containing RNA. Top: snoRNA-73 (open), -74 (hatched), -50 (light gray); Middle: scaRNA-8 (stippled), -13 (brick), TERC (black);
Bottom: spliceosomal RNA (snRNA-U2 (wavy)) and box C/D-containing RNA (snoRNA-U3 (checkered)) levels. A related box C/D snoRNA-U13 (dark
gray) levels are not influenced by GRIM-1. B) Levels of the indicated RNA upon GRIM-1 depletion in HeLa cells. GRIM-1-depleted cells (GS) show
increased box H/ACA-containing RNA. Top: snoRNA-73, -74 and -50; Middle: scaRNA-8, -13, TERC; Bottom: snRNA-U2 and snoRNA-U3 levels. A related
box C/D snoRNA-U13 levels is not influenced by GRIM-1. Bar patterns same as in (A). **, p,0.01.
doi:10.1371/journal.pone.0024082.g003
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While these studies were in progress, a report demonstrating the
binding of SHQ1 to DKC1 in vitro [28] appeared. Therefore, we
tested whether GRIM-1 can bind DKC1 in mammalian cells.
DKC1 levels were very similar in vector- and GRIM-1 isoform-
expressing cells (Figure 6A). We next performed IP and WB
analyses for assessing the interactions between DKC1 and GRIM-
1. Dyskerin and GRIM-1 isoforms interacted with each other in a
manner similar to NAF1 (Figures 6B & C).
Box H/ACA RNA-bound Dyskerin levels are low in GRIM-
1-expressing cells
In light of the interactions between NAF1-GRIM-1 and DKC1-
GRIM-1, we hypothesized DKC1 to be delocalized as the core
trimer requires NAF1 to be functional. To address this, we
resorted to RNP-IP, which would address whether DKC1
associated with nascent box H/ACA RNA. DKC1-specific
antibody was used in RNP-IP of cross-linked lysates from
GRIM-1 isoform-expressing cells. RNA recovered from the IP
products was quantified using real-time PCR. These analyses
indicated that a pool of DKC1 was devoid of box H/ACA RNAs
(Figure 6D) in the presence of GRIM-1 isoforms.
Yeast Shq1p exerts GRIM-1a-like effects in mammalian
cells
Since Shq1p was critical for viability and growth in yeast, we
next determined how it behaved in human cells. To address this,
we expressed N-terminally FLAG-tagged Shq1p in GRIM-1-
depleted HeLa cells (Figure 7A) and performed an IP analysis to
detect its interaction with endogenous NAF1. Indeed, Shq1p
interacted with NAF1 (Figure 7B). However, to our surprise,
Shq1p caused growth inhibition (Figure 7C) like GRIM-1a. This
observation prompted us to analyze steady-state levels of box H/
ACA RNA in Shq1p-expressing cells. GRIM-1a-reconstituted
cells were used as a positive control for this experiment. Indeed,
box H/ACA RNA levels were suppressed very similarly by Shq1p
and GRIM-1a (Figure 7D) compared to their respective controls.
Next, we analyzed 18S rRNA processing in these two cell lines.
The levels of unprocessed 18S rRNA increased significantly
(p,0.05) in Shq1p- and GRIM-1a-expressing cells (Figure 7E). As
observed with GRIM-1, Shq1p also accumulated more in the
cytoplasm (Figure 7F).
GRIM-1 expression is lost in human primary tumors
To determine the pathologic relevance of GRIM-1, we subjected
the NCI-TARP human tissue array to immunohistochemical
analysis with a mouse GRIM-1-specific antibody (Figure 8A). Based
on the intensity of GRIM-1 signals (low to high) we categorized
them arbitrarily into five groups. The prostate specimens had
normal (n=38) and tumor (n=46) tissues, among which 24 were
patient-matched.Statistical analysisoftheprostate tumorsindicated
that 100% of the samples showed loss/reduction compared to their
normal tissues with severe loss/reduction observed in 75% of the
samples (Table 1). These observations suggest a potential tumor
suppressor-like function for GRIM-1. These data are also consistent
with our recent demonstration of GRIM-1 isoforms suppress tumor
xenograft growth in mice [8].
We further examined GRIM-1 in patient-matched prostate
specimens of 4 patients (NCI CHTN) that had tumor content from
Figure 4. GRIM-1 regulates small non-coding RNA levels. A) Construction of shRNA-resistant GRIM-1 variant. Top: GRIM-1 shRNA-targeted
region showing the wild-type sequence (WT Seq) and their corresponding amino acids (AA Seq) number (Codon No). Base changes coding for the
same amino acids are underlined in the variant sequence (Var Seq). Bottom: GRIM-1 shRNA does not target the variant sequence for silencing.
Expression of Myc-tagged GRIM-1
Var isoforms in GRIM-1-depleted cells. Actin was used as a loading control. B) The repressive effect of GRIM-1 on
small non-coding RNA reappears upon GRIM-1
Var expression in GRIM-1-depleted cells (GS). Levels of the indicated RNA in HeLa cells stably expressing
Myc-tagged GRIM-1
Var isoforms. GRIM-1
Var isoforms differentially suppress snoRNA-73, -74, -50, scaRNA-8, -13, TERC, snRNA-U2 and snoRNA-U3 levels.
A related box C/D snoRNA-U13 levels are not influenced by GRIM-1. Relative abundance was calculated with respect to spliceosomal RNA (snRNA-U6)
levels by real-time PCR. *, p,0.01; **, p,0.001. Numbers to the side in WB indicate positions of protein markers. Bar patterns same as in Figure 3.
doi:10.1371/journal.pone.0024082.g004
GRIM-1 Suppresses Sno/ScaRNA
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Since GRIM-1 spans ,100-kb region, we employed primers to
amplify the 11 individual exons (Table S2). Except for exon 2, we
were able to amplify all exons and found no point mutations (data
not shown). Because we could not get RNAs from these tumors, we
next determined GRIM-1 transcript levels in a non-oncogenic
prostate epithelial cell line RWPE-1 and a metastatic prostate
tumor cell line VCaP using qPCR. As shown in Figure 8B, there
was a significant reduction in the levels of GRIM-1 isoform-specific
ORF regions (Table S3) in VCaP compared to RWPE-1. The
GRIM-1a transcript level was extremely low in the tumor cell line.
Consistent with these observations, expression levels of RNU5,
Figure 5. GRIM-1-mediated effects on rRNA processing. A) A Modular representation of mammalian rRNA primary transcript. Top: Relative
positions of regions absent (thin lines) and present in the mature rRNA (solid lines). Bottom: Relative positions of primers used to analyze rRNA
processing. Primer (1 or A) is used for first-strand synthesis in RT. The Ct value obtained using primers 6/1 and F/A represent the total rRNA (mature
and unprocessed) present in the preparation. The Ct value obtained using two different primer sets (4/5 and 2/3) for 59ETS-18S and (D/E and B/C) for
ITS2-28S represent unprocessed rRNA present in the preparation. Primers 2 and 5 cannot amplify when 18S rRNA has matured. Similarly, primers B
and E cannot amplify when 28S rRNA has matured. B) GRIM-1 isoforms suppress rRNA processing. Isoform-specific inhibitory effects are evident on
59ETS-18S region with GRIM-1c being a potent inhibitor of processing and GRIM-1a is the least inhibitory. The values represent the averages of primer
pairs 4/5 (unprocessed) over 6/1 (total) and primer pairs 2/3 (unprocessed) over 6/1 (total) for 18S rRNA. C) Efficient processing of 18S rRNA regions in
GRIM-1-depleted cells (GS) compared to empty vector control (pLKO1; EV) and/or scrambled shRNA control (SC). Values were calculated as mentioned
above. D) Reappearance of the inhibitory effect on rRNA processing upon GRIM-1
Var expression in GRIM-1-depleted cells (GS). Isoform-specific effects
are evident on 59ETS-18S region. E) Efficient processing of 28S rRNA regions in GRIM-1-depleted cells (GS) compared to empty vector control (pLKO1;
EV) and/or scrambled shRNA control (SC). The values represent the averages of primer pairs D/E (unprocessed) over F/A (total) and primer pairs B/C
(unprocessed) over F/A (total) for 28S rRNA. F) GRIM-1
var isoforms show inhibitory effect on ITS2-28S region. GRIM-1b
var and GRIM-1c
var exert similar
inhibitory effect while GRIM-1a
var is less inhibitory on ITS2-28S rRNA processing. *, p,0.01; **, p,0.001.
doi:10.1371/journal.pone.0024082.g005
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compared to RWPE1.
Discussion
GRIM-1 is a novel IFN-induced growth regulator [8]. IFNs are
known to regulate a number of post-transcriptional processes that
modulate several cellular responses [29]. Two well-studied IFN-
inducible proteins viz., PKR and RNaseL affect protein synthesis
and mRNA stability, respectively. Activated PKR phosphorylates
eIF-2a leading to an inhibition of cap-dependent translational
initiation [30–32]. The IFN-inducible OAS, which produce 29,5 9-
linked oligoadenylates [33,34] activate a latent endoribonuclease,
RNaseL, which cleaves certain cellular RNAs to regulate cellular
and viral growth [3,35]. A third IFN-inducible protein, p56
inhibits translation by associating with eIF-3 [4]. IFN-induced
mTOR signaling pathway suppresses protein translation via
phosphorylation of eIF4E-BP. In this study, we defined another
novel IFN-inducible mechanism that regulates cell growth by
controlling RNA metabolism. Maturation of rRNA is controlled
by snoRNPs, a group of small non-coding RNA-containing nucleolar
protein complexes.Wedescribed herehow GRIM-1[8] controlsthis
process at the stage of snoRNP biogenesis, by delocalization of
NAF1, a factor necessary for snoRNP maturation. The mechanism
of GRIM-1 action appears to be distinct from that of another IFN-
inducible gene product ISG20 [36] although the latter also affected
mature rRNA levels.
Our current understanding of rRNA biogenesis is primarily
based on literature from the budding yeast. However, the mecha-
nisms that control it in mammalian cells are unclear. In yeast,
Shq1p complexes with another protein, Naf1p and both these
proteins were required for viability [18]. However, significant
differences exist between GRIM-1 and Shq1p: 1) unlike the yeast
shq1, GRIM-1 mRNA codes for three isoforms that differentially
affect cell growth and rRNA biogenesis; 2) sequence differences
between GRIM-1 and Shq1p; and 3) depletionof Shq1p suppressed
cell viability. In contrast, depletion of GRIM-1 provided growth
advantageinpresence ofIFNwhileoverexpressioncausedapoptosis
(Figure 1). Despite these functional differences, we found NAF1-
GRIM-1 and NAF1-Shq1p physical interactions occur in human
cells (Figures 2 & 7). However, both GRIM-1 and Shq1p caused
growth suppression upon reconstitution into GRIM-1-depleted
human cells. Consistent with a report that Shq1p interacted with
another yeast protein Cbf5p [20], we found DKC1 binds to GRIM-
1 (Figure 6). Interestingly, SHQ1 interacted only with DKC1 and
not with NAF1; while DKC1 bound either SHQ1 or NAF1 and
excess NAF1 could displace SHQ1 from DKC1 in vitro [28]. Such
interpretations were primarily based on in vitro translated protein(s).
The N-terminal region of Shq1p appears to have a HSP20-like
domain found in co-chaperones of Hsp90 [37]. Interestingly,
human and yeast proteins show very high identities in this region.
However, a recent in vitro reconstitution studies demonstrated that
this HSP20-like domain in SHQ1 is dispensable for interactions
with DKC1 [28]. For example, GRIM-1b and GRIM-1c, which
lacked this domain, interacted with DKC1 (Figure 6). Since, the
HSP20-like domain is not required for stabilizing DKC1 as
originally proposed [28], we suggest that GRIM-1 may assist in the
opening up the inactive NAF1 homo-dimer, as seen in yeast Naf1p
[38], for interaction(s) with DKC1 and NOP10. This is consistent
with our observation that GRIM-1c, which lacks the HSP20-like
domain (but found in GRIM-1a) is able to co-IP more NAF1;
interact with DKC1 and exert toxic effects. Such low DKC1 levels
upregulate tumor suppressor p53 and CDK-inhibitor p21 levels to
exert growth suppression and/or apoptosis [39].
Depletion of Shq1p and/or Naf1p caused a severe loss in box
H/ACA RNA/RNP levels with concomitant defects in rRNA
processing that resulted in poor viability of yeast cells [18]. We
found that human GRIM-1 suppressed growth, by repressing box
H/ACA RNA levels and rRNA processing. Surprisingly, yeast
Shq1p behaved like GRIM-1a (Figure 7) upon its reconstitution in
Figure 6. GRIM-1 isoforms interact with endogenous Dyskerin in mammalian cells. HeLa cells transiently expressing Myc-tagged GRIM-1
isoforms were analyzed for interaction with Dyskerin using the indicated antibodies. A) Expression levels of Dyskerin (top) and actin (bottom) in the
indicated transfectants. No significant change in Dyskerin levels are observed upon GRIM-1 expression. B & C) Total cell lysates (signal-normalized
lysate amount) were subjected to IP with the indicated antibodies and subsequently probed with the indicated antibodies. All GRIM-1 isoforms
interact with Dyskerin. D) Quantification of Dyskerin-bound RNA in the indicated cell lines. RNA extracted following RNP-IP of cross-linked cell lysates
using Dyskerin-specific antibody, was used in RT and analyzed by real-time PCR using primers. Dyskerin-bound RNA levels are low in GRIM-1-
expressing cells. Majority of snoRNA-74 fraction is bound by Dyskerin (a box H/ACA core protein) while only a minor fraction of snoRNA-U3 is bound
by Dyskerin. Open bars represent RNA levels (total) in cells, Checkered bars represent Dyskerin-bound RNA levels in cells and Solid bars represent
RNP-IP performed using an IgG control. *, p,0.01; **, p,0.001. Numbers to the side in WB indicate positions of protein markers.
doi:10.1371/journal.pone.0024082.g006
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proteins do not appear to account for their functional differences.
On a similar note, depletion of SHQ1 in HeLa cells impacted
levels of E1 (U17) and E3 H/ACA RNAs far less than DKC1
(NAP57) depletion [28]. Based on these observations we suggest
that GRIM-1/Shq1p need not necessarily be a cell survival factor.
Many cellular factors including p53 and the MAP kinases of JNK
subgroup act in a yin-yang manner in cell growth regulation [40–
42]. We and others have shown earlier that thioredoxin and
thioredoxin reductase which are critical players in cellular redox
control, also act as growth suppressors. Thus, depending on
the cellular environment GRIM-1 may act as a survival or
growth-suppressive factor. Such activities may depend on the post-
translational modifications and association(s) with other cellular
factor(s), whose identities is/are unclear at this stage. The C-
terminal region of GRIM-1 is rich in serine/threonine residues, a
feature absent in Shq1p, may explain in part its anti-cellular
effects. One clear difference between human GRIM-1 and Shq1p
is the absence of caspase-cleavage sites in the latter. Furthermore,
yeast does not have a known caspase. Unlike Shq1p, GRIM-1
produces three isoforms. These differences could account for
differential behavior of GRIM-1 and Shq1p in their respective
species. It is also likely that GRIM-1/Shq1p might interact with
some undefined cellular factors (absent in yeast) in mammalian
cells to exert growth suppression. Even though, box H/ACA and
C/D snoRNA assembles into RNPs with different protein factors,
unexpectedly box C/D snoRNA-U3 level was also suppressed by
GRIM-1 isoforms (Figures 3 & 4). This observation is similar to
earlier reports that documented a drop in C/D snoRNA-U3
(,45%) levels upon DKC1 depletion [22] and drop in C/D
snoRNA-U24 (,40%) and C/D snR78 (,25%) levels upon
Naf1p depletion [43]. Since, majority of NAF1 molecules were
delocalized in presence of GRIM-1 (Figure 2), certain box C/D
snoRNA levels e.g. U3 may also drop. When this manuscript was
under preparation, a report that DKC1 was necessary for cell
division but not cell survival appeared. In this study, fibrillarin, the
enzymatic component of box C/D RNP, did not localize to
nucleoli in DKC1-null cells and such cells could survive for 3
months [39]. This observation further supports our notion that
DKC1 may be required for proper localization of, at least some if
not all, box C/D RNPs as snoRNA-U3 is detectable in RNP-IPs
using DKC1 antibody (Figure 6). On a similar note, DC mutations
Figure 7. Yeast Shq1p protein exhibits GRIM-1a-like behavior in mammalian cells. A) Expression of FLAG-tagged Shq1p in GRIM-1-
depleted HeLa cells ascertained by WB. B) Shq1p interacts with endogenous NAF1. IP and WB analysis were performed as described previously with
the indicated antibodies. C) Growth assay of empty vector control (VC-F; ¤), Shq1p-expressing (&) and GRIM-1a-expressing (m) cells. D) Box H/ACA
RNA levels are suppressed by Shq1p and GRIM-1a to a similar extent. Bar patterns are: pCXN2-FLAG vector (Open; VC-F), FLAG-Shq1p (Hatched;
Shq1p), pCXN2-Myc vector (Stippled; VC-M) and Myc-tagged GRIM-1a (Solid; 1a). E) Inhibition of 18S rRNA processing by Shq1p and GRIM-1a are
similar. Bar patterns as in D. The values represent the averages of primer pairs 4/5 (unprocessed) over 6/1 (total) and primer pairs 2/3 (unprocessed)
over 6/1 (total) for 18S rRNA. See Fig. 5 legend for additional information. F) Over-expressed Shq1p more accumulates in the cytoplasm. Confocal
images showing more Shq1p in the cytoplasm compared to the nucleus. *, p,0.01. Numbers to the side in WB indicate positions of protein markers.
doi:10.1371/journal.pone.0024082.g007
GRIM-1 Suppresses Sno/ScaRNA
PLoS ONE | www.plosone.org 9 September 2011 | Volume 6 | Issue 9 | e24082found in NHP2 and NOP10 affected pre-RNP assembly but not
tetramer formation [44], while mutations in DKC1 either
weakened or enhanced its association with SHQ1 [44,45]. Thus,
inefficient DKC1 activity appears to be the primary reason for
shortened telomeres in individuals with DC; and such effects may
be exerted on tercRNP levels by GRIM-1 expression.
In eukaryotes, rRNA and snRNA undergo maturation-associ-
ated pseudouridylation mediated by sno and scaRNPs, respec-
tively [46,47] while box C/D snoRNPs methylate the ribose
moieties of specific nucleobases [48,49]. The number of such
modifications increases with the complexity of the organism
though the same protein machinery performs the task by
increasing its RNA repertoire to target different sites. The precise
role of these two modifications is not clear although box C/D and
H/ACA RNA expression levels differ in a tissue-specific manner
[50]. All eukaryotic box H/ACA sno/scaRNAs require a core
protein machinery comprising of four highly-conserved proteins,
and mutations in them are rare e.g. DKC1 [51], NOP10 [52] and
NHP2 [53]. X-linked DC is caused by mutations in DKC1, are
characterized by bone marrow failure and increased susceptibility
to cancer [12,54]. DKC1 activity was required for rRNA
modifications that mediate IRES-mediated translation initiation
of cellular and viral RNAs. Translation of mRNAs coding for
XIAP and Bcl-XL, were severely affected in Dkc1
m cells [55].
Consistent with its growth-suppressive property, we found that
GRIM-1 expression and/or levels is/are suppressed in human
prostate cancers (Figure 8). This observation agrees to our earlier
report that GRIM-1 mRNA levels in cancer cell lines are very low
and IFN induced them to varying degrees while over expression of
GRIM-1 isoforms suppressed growth of tumor xenografts [8],
establishing an important link between rRNA metabolism and
tumor growth suppression. Interestingly, chicks imposed with
retinal defocus, upregulate SHQ1 levels to stop ocular growth
[56]. More importantly, a very recent study reported deletion of
SHQ1 locus in primary prostate cancers [17] suggesting it to be a
cooperative tumor suppressor. This observation independently
supports our finding that prostate cancers show severe loss of
GRIM-1 expression (Figure 8) that attests to a growth-suppressive
function in mammals.
Although ribosomal RNA and ribosomes are seen as constitu-
tively active components of pro-growth and pro-survival pathways,
a number of recent studies have shown that certain ribosomal
proteins act as tumor suppressors [57]. Certain snoRNAs, such as
ACA45, have been shown to possess miRNA-like functions and
regulate functions beyond their presently perceived notion that
they primarily regulate rRNA metabolism [58]. In some cases, low
levels of certain snoRNAs such as RNU44, RNU48 and RNU43
have been correlated with poor prognosis of breast and head and
neck squamous cell carcinomas [59]. Abnormal ribosome
biogenesis has been shown to result in chromosomal instability
[60]. An earlier study reported that IFN-b down regulated the
expression of RPL23A in some melanoma cells to achieve growth
suppression [61]. Thus, IFNs appear to target different compo-
nents of translational machinery to achieve tumor growth
suppression.
Finally, an important question arises as to why eukaryotes need
two additional factors for H/ACA RNP biogenesis when archea
have none? It was proposed that SHQ1 and NAF1, the assembly
factors, act sequentially on DKC1 [28]. From previous studies it is
clear that depletion of NAF1/Naf1p has more profound effects on
DKC1/Cbf5p levels than does SHQ1/Shq1p depletion [18,22].
Hence, we believe SHQ1 and NAF1 regulate box H/ACA RNA/
RNP levels in a negative and positive manner, respectively in
mammals.
Figure 8. GRIM-1 expression is lost in prostatic epithelial cells.
A) NCI-TARP array was analyzed by immunohistochemistry as per
standard procedures. A representative patient-matched sample show-
ing low expression of GRIM-1 (brown signals) in prostate tumors
compared to normal prostate. See Table 1 for additional information. B)
GRIM-1 mRNA levels are low in VCaP compared to RWPE-1 as analyzed
by qPCR while the other indicated RNAs are high in VCaP compared to
RWPE-1 cell line. GRIM-1 mRNA levels were analyzed using three
different primer pairs (Table S3). *, p,0.01; **, p,0.001.
doi:10.1371/journal.pone.0024082.g008
Table 1. GRIM-1 expression levels in normal and tumor specimens analyzed by immunohistochemistry.
Level@ R Normal Tumor Loss (%)
+ ++ +++ ++++ +++++ Total + ++ +++ ++++ +++++ Total
Prostate 4 5 7 14 8 38 21 17 8 46
Prostate (paired) 3 3 4 8 6 24 71 1 6 24 75
@Expression level graded on an arbitrary scale (%) using signal ratio of GRIM-1 to DAPI.
+ (0–20) – Severe loss, ++ (21–40) – Significant loss, +++ (41–60) – Moderate loss, ++++ (61–80) – Slight loss, +++++ (81–100) – No loss.
doi:10.1371/journal.pone.0024082.t001
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